They have $48m on hand. They spent about $8.5m in the quarter but that included a huge grant receipt of over $5m. They also have contingent payouts totaling $20m. If they have to pay the $20m it would mean they’ve hit their targets (which is hopefully a good thing), but still, this business is going to need significantly more money than they have and given the number of raises they’ve done the appetite for shareholders to continue paying up is going to dwindle. The more worrying thing is how little the sales they have made have impacted the top line/ cash receipts. Impedimed 2.0.
Ann: Quarterly Activity Report and Appendix 4C for Q2 FY2024, page-12
-
- There are more pages in this discussion • 23 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add 4DX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
52.5¢ |
Change
-0.005(0.94%) |
Mkt cap ! $215.4M | |||
| Open | High | Low | Value | Volume |
| 52.5¢ | 53.0¢ | 51.5¢ | $146.0K | 279.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 21156 | 52.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 54.0¢ | 310 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| 4DX (ASX) Chart |